Strasbourg biotech appoints ceo
Mark Bloomfield aims to accelerate sales growth at Polyplus-transfection
Bloomfield replaces Frédéric Perraud who continues with Polyplus as chief operating officer and deputy ceo.
Polyplus is planning to accelerate revenue growth by launching reagents and solutions for cell transfection applications, by the commercialisation of ZNA technology through licensing agreements with Sigma-Aldrich and Metabion, as well as geographical sales channel expansion with partners in the US and major European and Asian markets.
Bloomfield has a background in chemistry and joins Polyplus-transfection after more than 15 years in sales and management positions with global companies in the biotechnology tools and analytical instruments markets.
‘I am very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth,’ said Bloomfield.
You may also like
Pharmaceutical
Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024
Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists